[go: up one dir, main page]

WO2008143879A3 - Complément de vitamine e destiné à réduire les risques d'événements cardio-vasculaires chez des individus souffrant de diabète sucré et à génotype hp 2-2 - Google Patents

Complément de vitamine e destiné à réduire les risques d'événements cardio-vasculaires chez des individus souffrant de diabète sucré et à génotype hp 2-2 Download PDF

Info

Publication number
WO2008143879A3
WO2008143879A3 PCT/US2008/006157 US2008006157W WO2008143879A3 WO 2008143879 A3 WO2008143879 A3 WO 2008143879A3 US 2008006157 W US2008006157 W US 2008006157W WO 2008143879 A3 WO2008143879 A3 WO 2008143879A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
individuals
cardiovascular events
supplementation
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/006157
Other languages
English (en)
Other versions
WO2008143879A2 (fr
Inventor
Andrew Levy
Noah Berkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rappaport Family Institute for Research in the Medical Sciences
Synvista Therapeutics Inc
Original Assignee
Rappaport Family Institute for Research in the Medical Sciences
Synvista Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/798,488 external-priority patent/US20080044399A1/en
Application filed by Rappaport Family Institute for Research in the Medical Sciences, Synvista Therapeutics Inc filed Critical Rappaport Family Institute for Research in the Medical Sciences
Publication of WO2008143879A2 publication Critical patent/WO2008143879A2/fr
Publication of WO2008143879A3 publication Critical patent/WO2008143879A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/24—Resetting means

Landscapes

  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Méthodes et compositions permettant de déterminer l'avantage procuré par la prise de vitamine E pour le traitement d'événements cardio-vasculaires chez des individus souffrant de diabète sucré sur la base de leur phénotype d'haptoglobine et pour un tel traitement par la vitamine e E sur la base du phénotype d'haptoglobine.
PCT/US2008/006157 2007-05-14 2008-05-14 Complément de vitamine e destiné à réduire les risques d'événements cardio-vasculaires chez des individus souffrant de diabète sucré et à génotype hp 2-2 Ceased WO2008143879A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/748,177 2003-12-31
US11/798,488 US20080044399A1 (en) 2000-04-20 2007-05-14 Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype
US74817707 2007-05-14

Publications (2)

Publication Number Publication Date
WO2008143879A2 WO2008143879A2 (fr) 2008-11-27
WO2008143879A3 true WO2008143879A3 (fr) 2009-01-22

Family

ID=86398036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006157 Ceased WO2008143879A2 (fr) 2007-05-14 2008-05-14 Complément de vitamine e destiné à réduire les risques d'événements cardio-vasculaires chez des individus souffrant de diabète sucré et à génotype hp 2-2

Country Status (1)

Country Link
WO (1) WO2008143879A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229244A1 (en) * 2000-04-20 2004-11-18 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229244A1 (en) * 2000-04-20 2004-11-18 Rappaport Family Institute For Research In The Medical Sciences Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients

Also Published As

Publication number Publication date
WO2008143879A2 (fr) 2008-11-27

Similar Documents

Publication Publication Date Title
ZA200708361B (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
WO2008042231A3 (fr) Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
WO2009158033A3 (fr) Antagonistes d’activine-actriia et utilisations pour augmenter les taux d’érythrocytes
WO2008097277A3 (fr) Expression tcl1 dans la leucémie lymphocytaire chronique (llc) régulée par mir-29 et mir-181
WO2008076437A3 (fr) Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges
WO2008024473A3 (fr) Cartographie d'interactions génomiques
WO2011038155A3 (fr) Analyse génétique
WO2010005982A3 (fr) Biomarqueurs multiplexés de résistance à l'insuline
WO2009120810A3 (fr) Troubles neurodégénératifs
EP2134245A4 (fr) Centre de test autonome permettant de tester la vision et la coordination
WO2009045505A3 (fr) Composition de prohormone et méthode d'utilisation
WO2007122382A3 (fr) Lycopène pour le traitement d'une dysmétabolie
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
AP2011005599A0 (en) Reconstituted rice kernels and processes for theirpreparation.
EP2205771A4 (fr) Procédé, alliage et composant
EP2134246A4 (fr) Centre de test autonome de vision et de neuro-traitement
WO2007084861A3 (fr) Compositions et procédés à base de xénohormèse
WO2009098355A8 (fr) Nouvelle utilisation de probiotiques
WO2009051232A1 (fr) Procédé de détermination de l'auto-inducteur 2
WO2007038264A3 (fr) Methodes associees a gapr-1
WO2008143879A3 (fr) Complément de vitamine e destiné à réduire les risques d'événements cardio-vasculaires chez des individus souffrant de diabète sucré et à génotype hp 2-2
WO2007011757A8 (fr) Utilisation d'inhibiteurs de la voie ubiquitine-proteasome pour augmenter la contractilite cardiaque
WO2011011733A3 (fr) Thérapie de remplacement de facteur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754449

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754449

Country of ref document: EP

Kind code of ref document: A2